HC5 Stock Chart & Stats
€19.57
€0.26(1.35%)
At close: 4:00 PM EDT
€19.57
€0.26(1.35%)
Day’s Range― - ―
52-Week Range€13.30 - €20.03
Previous CloseN/A
Volume0.00
Average Volume (3M)25.00
Market Cap
€13.10B
Enterprise Value€25.02K
Total Cash (Recent Filing)€1.63B
Total Debt (Recent Filing)€10.32B
Price to Earnings (P/E)61.8
Beta0.25
Next Earnings
Oct 22, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding689,527,300
10 Day Avg. Volume71
30 Day Avg. Volume25
Financial Highlights & Ratios
PEG Ratio-2.23
Price to Book (P/B)1.49
Price to Sales (P/S)3.97
P/FCF Ratio8.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.60Price Target Upside0.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.34
Revenue Forecast (FY)€2.58B
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquidityLower leverage and large available liquidity materially improve financial flexibility for a REIT with development and capital recycling needs. Sustained sub-5x net debt/EBITDA and ample cash reduce refinancing risk, enable opportunistic buybacks or JV capital and support dividend coverage over the next several quarters.
Strategic JV PartnershipsAccess to Brookfield/Blackstone capital that preserves majority control is a durable structural advantage: it frees balance-sheet capacity, accelerates portfolio recycling, and supplies non-dilutive funding for development or opportunistic repurchases, improving long-term ROE and execution optionality.
Diversified Operating MomentumHigh outpatient occupancy with steady re-leasing spreads and strong senior housing growth via Janus provide stable, diversified cash flows. This mix reduces dependence on any single submarket and supports predictable rent roll and NOI growth over multiple quarters despite pockets of lab weakness.
Bears Say
Lab Occupancy GapLab space recovery remains incomplete and requires net absorption to drive NOI inflection. Long leasing cycles, tenant diligence, and conversion time mean lab cash flows could lag other portfolio segments for many quarters, constraining overall portfolio NOI upside and rent roll stability.
Cash-flow And Margin VolatilitySharp negative FCF growth and a sudden gross margin decline reduce predictability of internal funding for capex, dividends and buybacks. For a cash-distributing REIT, volatile cash conversion undermines confidence in sustainably funding returns and increases reliance on capital recycling or external financing.
Higher Capital Costs And Redevelopment NeedsHigher cost of debt limits attractive leverage deployment and increases hurdle for accretive deals. Meanwhile, sizeable redevelopment/tenant-improvement needs raise near-term cash demands and capex intensity, pressuring returns and slowing conversion of vacant or second-gen space to income-producing assets.
HC5 FAQ
What was Healthpeak Properties, Inc.’s price range in the past 12 months?
Healthpeak Properties, Inc. lowest stock price was €13.30 and its highest was €20.03 in the past 12 months.
What is Healthpeak Properties, Inc.’s market cap?
Healthpeak Properties, Inc.’s market cap is €13.10B.
When is Healthpeak Properties, Inc.’s upcoming earnings report date?
Healthpeak Properties, Inc.’s upcoming earnings report date is Oct 22, 2026 which is in 57 days.
How were Healthpeak Properties, Inc.’s earnings last quarter?
Healthpeak Properties, Inc. released its earnings results on Aug 04, 2026. The company reported €0.068 earnings per share for the quarter, beating the consensus estimate of €0.024 by €0.044.
Is Healthpeak Properties, Inc. overvalued?
According to Wall Street analysts Healthpeak Properties, Inc.’s price is currently Undervalued.
Does Healthpeak Properties, Inc. pay dividends?
Healthpeak Properties, Inc. does not currently pay dividends.
What is Healthpeak Properties, Inc.’s EPS estimate?
Healthpeak Properties, Inc.’s EPS estimate is 0.05.
How many shares outstanding does Healthpeak Properties, Inc. have?
Healthpeak Properties, Inc. has 689,527,300 shares outstanding.
What happened to Healthpeak Properties, Inc.’s price movement after its last earnings report?
Healthpeak Properties, Inc. reported an EPS of €0.068 in its last earnings report, beating expectations of €0.024. Following the earnings report the stock price went up 1.016%.
Which hedge fund is a major shareholder of Healthpeak Properties, Inc.?
Currently, no hedge funds are holding shares in DE:HC5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healthpeak Properties Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.60 (0.14% Upside)
€19.60 (0.14% Upside)
Blogger Sentiment
Bullish
DE:HC5 Sentiment 85%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.89%
12-Months-Change
Fundamentals
Return on Equity
5.70%
Trailing 12-Months
Asset Growth
9.44%
Trailing 12-Months
Company Description
Healthpeak Properties, Inc.
Healthpeak Properties, Inc. is an S&P 500 constituent operating as a fully integrated real estate investment trust (REIT). The firm is dedicated to the acquisition, management, and development of premier properties essential for both medical research and the provision of healthcare services.
HC5 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: strong balance sheet metrics (net debt/EBITDA 4.7x), sizable liquidity, large JV partnerships (Brookfield/Blackstone) that raise $1B+ in proceeds while preserving control, strong outpatient leasing (1.2M SF in Q2; occupancy to 90.7%), lab leasing momentum and occupancy improvement (78.5%, +140 bps YTD), and significant senior housing/Janus performance (45% revenue growth, 34% adjusted EBITDA growth). Challenges remain, notably lab occupancy still below peak, selective elevated CapEx needs for redevelopments, elevated borrowing costs limiting leverage options, cautious tenant timelines, and only a modest FFO guidance raise. Overall the positive operational momentum, strategic partnerships, and strong liquidity and balance sheet outweigh the remaining execution and market risks.View all DE:HC5 earnings summariesHC5 Revenue Breakdown
76.41% Rental and related revenues
21.40% Resident fees and services
2.19% Interest income and other

HC5 Stock 12 Month Forecast
Average Price Target
€19.60
▲(0.14% Upside)
Technical Analysis
National Health Investors
―
Omega Healthcare
―
Sabra Healthcare REIT
―
―
Healthcare Realty Trust
―










